Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service SI joint fusion cases in California: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 16% on average (37 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 9 | 448 | 48% |
| 2020 | 7 | 316 | 50% |
| 2021 | 13 | 548 | 52% |
| 2022 | 17 | 625 | 53% |
| 2023 | 15 | 515 | 55% |
| 2024 | 23 | 583 | 56% |
| 2025 from claims | – | 456 369–535 | 56% |
| 2026 forecast | – | 466 365–585 | 56% |
| 2027 forecast | – | 474 352–627 | 56% |
| 2028 forecast | – | 483 342–666 | 56% |
| 2029 forecast | – | 491 334–704 | 57% |
| 2030 forecast | – | 500 327–741 | 57% |
Minimally invasive and open sacroiliac joint fusion. Professional codes (what the surgeon bills): CPT 27279, 27280, 0775T, 27278.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 58% of the cases CMS names in California; 17 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 68% inpatient hospital, 32% surgery center. The share outside the hospital has moved +16 pts since 2019, so more of this market is decided in surgery centers and offices each year.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Arizona | 5 | 365+24%/yr | +24%/yr | 0.4 | 67% | 950 in 2030+17%/yr |
| Colorado | 9 | 330+20%/yr | +20%/yr | 0.6 | 11% | 570 in 2030+9.4%/yr |
| Washington | 4 | 187−0.2%/yr | −0.2%/yr | 0.2 | 100% | 80 in 2030−12%/yr |
| Idaho | 2 | 102+43%/yr | +43%/yr | 0.5 | 0% | 170 in 2030+8.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 219 | 9,586−3.4%/yr | −3.4%/yr | 2.80.8× | 7% | 10,100 in 2030+0.8%/yr |
| Lumbar fusion | 199 | 8,753−1%/yr | −1%/yr | 2.50.8× | 2% | 9,020 in 2030+0.5%/yr |
| Cervical fusion & disc arthroplasty | 77 | 3,603−4%/yr | −4%/yr | 1.00.7× | 0% | 4,270 in 2030+2.9%/yr |
| Kyphoplasty & vertebroplasty | 23 | 2,826−4.2%/yr | −4.2%/yr | 0.80.8× | 27% | 3,540 in 2030+3.8%/yr |
SI joint fusion in every state, and its device makers · Every procedure market in California · Every state · Compare with Arizona
SI-BONE leads with 75% of company spending on these surgeons in 2025, +16 pts on 2024.
In 2025, 8 companies reported engagement with California’s surgeons worth $277K in consulting, speaking, meals and travel tied to these products, about $12K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 7 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.